ValiRx engages US investor relations firm

RNS Number : 3712S

ValiRx PLC

17 March 2016

 

ValiRx Plc

("ValiRx" or "the Company")

VALIRX ENGAGES US INVESTOR RELATIONS FIRM

London, UK, 17^th March 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that subsequent to the Company's establishment of a US office (announced 05.11.15), the Group has engaged Burns McClellan, a leading US-based investor relations consultancy, on an on-going basis to help create broader recognition of the Company within the US life science investor community and to encourage and facilitate greater interaction with academic, clinical, and business leaders in ValiRx's areas of oncological development.

Burns McClellan, founded over 25 years ago, is a healthcare investor relations specialist with considerable experience of supporting products and businesses in oncology with a wide range of US-based investors.  During the annual J.P. Morgan healthcare conference in San Francisco in mid-January 2016, Burns McClellan conducted an institutional investor introductory programme for ValiRx, on a project basis, which the Company found beneficial and has been keen to accelerate.

Satu Vainikka, Chief Executive of ValiRx, commented: "I am pleased our relationship with Burns McClellan is developing strongly, and I look forward to the Company benefitting from enhanced engagement with US investors and other key partners in the US biotech sector."

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: [phone]
Tarquin Edwards, Head of Communications.	Tel: [phone] [e-mail]
Mark Treharne, Corporate Development Manager	Tel: [phone] [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser)	Tel: [phone]
Liam Murray / Avi Robinson
Northland Capital Partners Limited (Broker)	Tel: [phone]
Patrick Claridge / David Hignell (Corporate Finance) John Howes / Abigail Wayne (Broking)

About ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.

The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. It actively manages projects within its portfolio as a trading company.  The ValiRx business model spreads the risks of life science technology development by minimizing financial exposure and running a set of projects to defined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.

 2. ValiFinn is the biomarkers and diagnostic development division.  ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.

 3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.

 

END

 

 

NRAUBAVRNVAOARR